Nitroalkene Trolox Derivatives and Methods of Use Thereof In The Treatment And Prevention of Inflammation Related Conditions

ABSTRACT

The present invention is directed to a class of anti-inflammatory, antioxidant nitroalkene compounds used in biological or biochemical applications to reduce oxidative stress or damage. The nitroalkene compounds described herein further avoid disadvantageous metabolism currently present in this field.

BACKGROUND

The scope of the present invention includes compounds and pharmaceuticalcompositions useful as anti-inflammatory agents.

Studies have shown that endogenous electrophilic unsaturated-nitratedfatty acids, including nitro-linoleic acid (LNO₂) and nitro-oleic acid(OA-NO₂), can mediate anti-inflammatory and pro-survival signalingreactions [1]. The basis for the mediation are mainly produced becausethe presence of the nitro group on the double bond turns the β-carbonadjacent to the nitroalkene strongly electrophilic and reacts covalentlywith nucleophiles both in proteins (thiols and histidine residues) andlow molecular weight molecules via Michael addition reactions [2].

Thus, biological electrophiles have emerged as mediators protectingagainst xenobiotic and oxidant injury. The transcription factor Nrf2(nuclear factor erythroid 2-related factor 2)/Keap1 (Kelch-likeECH-associating protein) pathway mediates phase 2 gene activation [3].Under normal conditions, Nrf2 localizes to the cytoplasmic suppressorprotein Keap1 which has several critical cysteine residues that serve assensors to environmental stresses such as ROS and electrophiles [3, 4].Keap1 cysteines are oxidized or alkylated, causing a conformationalchange and liberating Nrf2 to translocate to the nucleus, bind to thecis-acting DNA regulatory antioxidant response element (ARE) and therebytransactivating Nrf2-dependent gene transcription [3, 4]. This includesenzymes involved in glutathione (GSH) metabolism, such as the subunitsof the rate-limiting enzyme of glutathione synthesis, glutamate-cysteineligase catalytic (GCLC) and modifier (GCLM) subunit genes. AlsoNAD(P)H:quinone oxidoreductase-1 (NQO1), which not only detoxifiesxenobiotic quinones, but also reduces antioxidants vitamin E andcoenzyme Q10 to their active form, is a Nrf2 target gene.

Additionally, HO-1 has been shown to be positively regulated by Nrf2 [5,6]. This widespread mechanism protects against metabolic andinflammatory stress [5, 7, 8]. It is interesting to note thatelectrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine151-independent mechanism [9]. Actually, nitrated oleic acid, one of theendogenous nitroalkenes, is a Cys(151)-independent Nrf2 activator, whichin turn can influence the pattern of gene expression and therapeuticactions of nitroalkenes [9].

Heme Oxygenase-1 (HO-1) also plays a central role in vascularinflammatory signaling and mediates a protective response toinflammatory stresses such as atherosclerosis, vascular restenosis andkidney diseases including transplant rejection [10]. Heme oxygenase 1catalyzes the degradation of heme to biliverdin, iron, and carbonmonoxide (CO). CO has been shown to display diverse, adaptive biologicalproperties, including anti-inflammatory, anti-apoptotic, andvasodilatory actions [11].

Nitrated fatty acids have also been shown to be activators of peroxisomeproliferator-activated receptor gamma (PPARγ). PPARγ is established as amaster regulator of metabolism, inflammation, adipogenesis, and insulinsensitization [12]. High, non-physiological concentrations of nativefatty acids (N50 μM), prostaglandin metabolites, and oxidized fatty acidderivatives are able to activate PPARγ, α, and δ [13,14]. Fatty acidscontaining an α-β-unsaturated ketone as a core structural element, suchas 15d-PGJ₂, also activate PPARγ [15]. Docking of 15d-PGJ₂ to the ligandbinding domain (LBD) shows that it is not sufficient to activate thereceptor; rather, a covalent Michael addition reaction (lockingreaction) is required for activation [13]. The PPARγ receptor contains acritical thiol (Cys285) in the LBD, with covalent modification of thishighly conserved Cys285 by thiol-reactive compounds sufficient to inducepartial receptor activation [16]. NO₂-FAs and keto-fatty acidderivatives have high binding affinities for PPAR isotypes, being PPARγthe most robustly-activated receptor [13,17]. The mechanism by whichLNO2 activates PPARγ has been determined with recent solution of thecrystal structure of PPARγ having LNO2 occupancy in the LBD [18,19].Differential conformational changes to PPARγ resulting from this uniqueendogenous ligand have the capacity to impart unique specificity to thedownstream signaling events resulting from PPARγ activation [13,19].Interestingly, PPARγ activation skews human monocytes toward ananti-inflammatory M2 phenotype [20], another possible mechanism tofurther explain the anti-inflammatory, anti-atherogenic properties ofendogenous nitroalkenes.

However, in vivo studies of nitrated fatty acids such as nitrated oleicacid (18:1-NO₂) metabolism showed that nitrated oleic acid undergoes arapid and substantial modification that affects subsequent chemicalreactivity and signaling actions [21]. More specifically, the results ofthe study showed the 18:1-NO₂ suffers rapid but reversible adduction toplasma thiols and GSH. Furthermore, a significant proportion of 18:1-NO₂and its metabolites are converted to nitroalkane derivatives bysaturation of the double bond, and to a lesser extent are desaturated todiene derivatives. The rapid saturation of the double bond decreases theelectrophilic character of the molecule and may consequently affect thepotency [22].

The study also showed that the hydrophobic nitro-oleic acid ismetabolized by the β-oxidation pathways. As a result, the β-oxidizedmetabolite will be less hydrophobic and this will not only influencepartitioning between hydrophobic and hydrophilic compartments andconsequent tissue distribution, but can also affect chemical reactivityand pharmacological profiles by altering the specificity of thenitroalkenes to the biologically relevant targets.

Non-endogenous hydrophobic nitroalkene tocopherols and analogs thereof,as shown in WO 2015/073527, exhibit comparable potency asanti-inflammatory nitrated fatty acids and mimics transport processes ofother lipid molecules in vivo and is closely related to lipoproteinhomeostasis and metabolism which control intestinal absorption, trafficthrough the vascular compartment, and cellular uptake [20]. However,poor hydrosolubility of the nitroalkene tocopherol presents difficultiesfor traditional routes of drug delivery. Consequently, as discussed, invivo distribution is premised on simulating the transport mechanism ofendogenous lipid molecules.

A new family of nitroalkenes trolox (the hydrosoluble form ofalpha-tocopherol) derivatives, provides advantages of controllinghydrosolubility, in doing so the scope of the invention includeshydrosoluble nitroalkene trolox derivatives to very hydrophobic ones.This allows the new generation of nitroalkenes to be modified fordifferent inflammation related conditions.

SUMMARY

Within the scope of the present invention a new class of non-endogenousnitroalkene derivatives of6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) whichare water soluble. The water soluble non-endogenous nitroalkene troloxderivatives within the scope of the invention allows for absorption anddistribution along the lines of “classical” non-steroidalanti-inflammatory drugs (NSAIDs), but activates cell signaling pathwaysdue to the presence of the nitroalkenyl functional group. This new classof anti-inflammatory compounds exerts a wide range of anti-inflammatory,anti-proliferative and anti-platelet actions by modifying five maj orsignaling pathways: inhibition of NfkB and inflammasome pathways;activation of Nerf2/Keap 1, PPAR-gamma and Heat Shock Response. Thenitroalkene trolox derivatives herein described exert all thesesignaling effects with the advantage of controlling water solubility.Further, the new generation of nitroalkene trolox derivatives are not assusceptible to beta oxidation or metabolism via the classicaldesaturation pathway.

Water solubility of the compounds described herein is modified by thesaturated hydrocarbon chain length of the nitro alkene, such that thescope of the invention includes hydrosoluble to hydrophobic nitroalkenetrolox derivatives.

One embodiment within the scope of the invention is a compound ofFormula I:

or a pharmaceutically-acceptable salt thereof, wherein R is a C₁-C₁₅nitroalkenyl; R¹, R², R⁴, and R⁵ are independently a —H or —CH₃; and R³is selected from the group consisting of —H, —OH, —OBOC, —OCH₃, —OBn,—SH, —NO₂, —NH₂, —CN, a carbonyl, a sulfonate, an amidino.

The compound of Formula I, wherein R³ is selected from the groupconsisting of —H, a —OH, —OBOC, —OCH₃, and —OBn.

Another embodiment includes the compound of Formula I, wherein R¹, R²,R⁴, and R⁵ are each —CH₃.

Another embodiment includes the compound of Formula I, wherein R is anitrovinyl.

Another embodiment includes the compound of Formula I, wherein R³ is—OH.

Another embodiment is a compound that is2,5,7,8-tetramethyl-2-(2-nitrovinyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(2-nitropentenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(2-nitro-2-pentenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(3-nitro-2-pentenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(3-nitro-3-pentenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(4-nitro-3-pentenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(4-nitro-4-pentenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(5-nitro-4-pentenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(2-nitrooctenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(2-nitro-2-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(3-nitro-2-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(3-nitro-3-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(4-nitro-3-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(4-nitro-4-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(5-nitro-4-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(5-nitro-5-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(6-nitro-5-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(6-nitro-6-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(7-nitro-6-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(7-nitro-7-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(8-nitro-7-octenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(2-nitrotridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(2-nitro-2-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(3-nitro-2-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(3-nitro-3-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(4-nitro-3-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(4-nitro-4-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(5-nitro-4-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(5-nitro-5-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(6-nitro-5-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(6-nitro-6-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(7-nitro-6-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(7-nitro-7-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(8-nitro-7-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(8-nitro-8-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(9-nitro-8-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(9-nitro-9-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(10-nitro-9-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(10-nitro-10-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(11-nitro-10-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(11-nitro-11-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(12-nitro-11-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(12-nitro-12-tridecenyl)chroman-6-ol;2,5,7,8-tetramethyl-2-(13-nitro-12-tridecenyl)chroman-6-ol, or aphysiologically acceptable salt thereof.

Another embodiment is the compound(2S)-2,5,7,8-tetramethyl-2-[(E)-2-nitrovinyl]chroman-6-ol or aphysiologically acceptable salt thereof.

Another embodiment includes the compound of Formula I, wherein R is a2-nitrovinyl and the absolute configuration of the chiral carbonadjacent the oxygen atom on the chromanol ring structure is (S).

Another embodiment includes the compound of Formula I, wherein R is a2-nitroalkenyl and the absolute configuration of the chiral carbonadjacent the oxygen atom on the chromanol ring structure is (S).

Another embodiment includes the compound of Formula I, wherein R is a3-nitroallyl and the absolute configuration of the chiral carbonadjacent the oxygen atom on the chromanol ring structure is (S).

Another embodiment includes the compound of Formula I, wherein R is a3-nitroalkenyl and the absolute configuration of the chiral carbonadjacent the oxygen atom on the chromanol ring structure is (S).

Another embodiment includes the compound of Formula I, wherein R has anitroalkenyl disposed at fourth to fifteenth carbon on the C₄-C₁₅hydrocarbon tail and the absolute configuration of the chiral carbonadjacent the oxygen atom on the chromanol ring structure is (R).

Another embodiment includes a pharmaceutical composition comprising acompound of Formula I and a carrier.

Another embodiment includes a method of treating inflammation relateddisorders comprising the steps of administering to a subject in needthereof a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically-acceptable salt thereof, wherein R is a C₁-C₁₅nitroalkenyl; R¹, R², R⁴, and R⁵ are independently a —H or —CH₃; and R³is selected from the group consisting of —H, —OH, —OBOC, —OCH₃, —OBn,—SH, —NO₂, —NH₂, —CN, a carbonyl, a sulfonate, an amidino.

Another embodiment includes a method of treating inflammation relateddisorders comprising the steps of administering to a subject in needthereof a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically-acceptable salt thereof, wherein R is a C₁-C₁₅nitroalkenyl; R¹, R², R⁴, and R⁵ are independently a —H or —CH₃; and R³is selected from the group consisting of —H, —OH, —OBOC, —OCH₃, —OBn,—SH, —NO₂, —NH₂, —CN, a carbonyl, a sulfonate, an amidino, wherein theinflammation related disorder is selected from the group consisting ofatherosclerosis, obesity, metabolic syndrome, arterial hypertension(HTA), acne vulgaris, asthma, autoimmune diseases, autoinflammatorydiseases, celiac disease, chronic prostatitis, glomerulonephritis,inflammatory bowel diseases, pelvic inflammatory disease, reperfusioninjury, rheumatoid arthritis, sacroidosis, transplant rejection,vasculitis, and interstitial cystitis.

Another embodiment includes a method of treating inflammation relateddisorders comprising the steps of administering to a subject in needthereof a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically-acceptable salt thereof, wherein R is anitro-alcohol or a C₁-C₁₅ nitroalkenyl; R¹, R², R⁴, and R⁵ areindependently a —H or —CH₃; and R³ is selected from the group consistingof —H, —OH, —OBOC, —OCH₃, —OBn, —SH, —NO₂, —NH₂, —CN, a carbonyl, asulfonate, an amidino, wherein the inflammation related disorder isatherosclerosis.

Another embodiment includes a method of treating inflammation relateddisorders comprising the steps of administering to a subject in needthereof a therapeutically effective amount of(E)-2,5,7,8-tetramethyl-2-(2-nitrovinyl)chroman-6-ol or aphysiologically acceptable salt thereof.

Another embodiment includes a method of preparing a compound of formulaI

or a pharmaceutically-acceptable salt thereof, wherein R is anitro-alcohol or a C₁-C₁₅ nitroalkenyl;R¹ is CH₃;R², R⁴, and R⁵ is —H; andR³ is —OH, a carbonyl, a sulfonate, an amidino which comprises treatinga compound of Formula II

wherein R⁶ is a C₁₋₆ alkyl with a protective group (Pro) in a polaraprotic solvent in the present of a nucleophilic catalyst to yield acompound of Formula III

followed by treating the compound of Formula III with a reducing agentin a polar aprotic solvent to reduce the COOR⁶ group to a primaryalcohol of Formula IV

followed by treating the compound of Formula IV with an oxidizingcatalyst and oxidizing reagent in a polar aprotic solvent to produce thecompound of Formula V

and followed by treating the compound of Formula V with a compound ofFormula VI

in the presence of a catalytic base to produce a compound of Formula VII

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B demonstrate changes in absorption spectra characteristicof adduct formation between sulfur moieties of β-mercaptoethanol withthe nitro vinyl β-carbon via Michael addition.

FIG. 2 demonstrates that the adduct formation follows a second orderrate constant.

FIG. 3 further confirms adduct formation between sulfur moieties and thenitro vinyl β-carbon via Michael addition, but demonstrated withglutathione.

FIG. 4 demonstrates that the adduct formation with the sulfur moiety inglutathione followed a second order rate reaction.

FIG. 5 provides Western Blot analysis to illustrate HO-1 and GCLMprotein expression by macrophage cell lines after exposure to NAT×0 orNAT×5.

FIGS. 6A and 6B demonstrates that NAT×0 did not induce an increase incell mortality nor did it protect cells when cells were activated withLPS.

FIGS. 7A and 7B illustrates inhibition of NLRP3 inflammasome activationat 20 μM of NAT×0 when applied with the first signal to activate theinflammasome (meaning NFkB related mechanisms) but already at 5 μM whenapplied together with the second inflammasome-activating signal (meaningpost-translational modification mechanism at the supramolecularinflammasome complex).

FIG. 8 presents cytotoxicity data of NAT×0 in RAW 264.7 murine cells.

FIG. 9 demonstrates control over the lipophilicity of the compounds,illustrating the scope of the molecules to range from water-soluble tofat-soluble as studied by RP-HPLC.

FIG. 10 illustrates the stability of NAT×0 in polyethylene glycol300-400 at 37° C.

FIG. 11 illustrates immunofluorescence and epifluorescence microscopyanalysis showing that NAT×0 inhibits nuclear translocation of NF-κB inTHP-1 macrophages.

FIG. 12 demonstrates the potent in vivo anti-inflammatory effects ofNAT×0 in C57BL/6 mice.

DETAILED DESCRIPTION

Before the present compositions and methods are described, it is to beunderstood that this invention is not limited to the particularprocesses, compositions, or methodologies described, as these may vary.It is also to be understood that the terminology used in the descriptionis for the purpose of describing the particular versions or embodimentsonly, and is not intended to limit the scope of the present inventionwhich will be limited only by the appended claims. Unless definedotherwise, all technical and scientific terms used herein have the samemeaning as commonly understood by one of ordinary skill in the art.Although any methods and materials similar or equivalent to thosedescribed herein can be used in the practice or testing of embodimentsof the present invention, the preferred methods, devices, and materialsare now described. All publications mentioned herein are incorporated byreference in their entirety. Nothing herein is to be construed as anadmission that the invention is not entitled to antedate such disclosureby virtue of prior invention.

It must also be noted that as used herein and in the appended claims,the singular forms “a,” “an,” and “the” include plural reference unlessthe context clearly dictates otherwise. Thus, for example, reference toa “cell” is a reference to one or more cells and equivalents thereofknown to those skilled in the art, and so forth.

As used herein, the term “about” means plus or minus 5% of the numericalvalue of the number with which it is being used. Therefore, about 50%means in the range of 45%-55%.

“Administering” when used in conjunction with a therapeutic means toadminister a therapeutic directly to a subject, whereby the agentpositively impacts the target. “Administering” a composition may beaccomplished by, for example, injection, oral administration, topicaladministration, or by these methods in combination with other knowntechniques. Such combination techniques include heating, radiation,ultrasound and the use of delivery agents. When a compound is providedin combination with one or more other active agents (e.g. otheranti-atherosclerotic agents such as the class of statins),“administration” and its variants are each understood to includeconcurrent and sequential provision of the compound or salt and otheragents.

By “pharmaceutically acceptable” it is meant the carrier, diluent,adjuvant, or excipient must be compatible with the other ingredients ofthe formulation and not deleterious to the recipient thereof.

“Composition” as used herein is intended to encompass a productcomprising the specified ingredients in the specified amounts, as wellas any product which results, directly or indirectly, from combinationof the specified ingredients in the specified amounts. Such term inrelation to “pharmaceutical composition” is intended to encompass aproduct comprising the active ingredient(s), and the inert ingredient(s)that make up the carrier, as well as any product which results, directlyor indirectly, from combination, complexation or aggregation of any twoor more of the ingredients, or from dissociation of one or more of theingredients, or from other types of reactions or interactions of one ormore of the ingredients. Accordingly, the pharmaceutical compositions ofthe present invention encompass any composition made by admixing acompound o the present invention and a pharmaceutically acceptablecarrier.

As used herein, the term “agent,” “active agent,” “therapeutic agent,”or “therapeutic” means a compound or composition utilized to treat,combat, ameliorate, prevent or improve an unwanted condition or diseaseof a patient. Furthermore, the term “agent,” “active agent,”“therapeutic agent,” or “therapeutic” encompasses a combination of oneor more of the compounds of the present invention.

A “therapeutically effective amount” or “effective amount” of acomposition is a predetermined amount calculated to achieve the desiredeffect, i.e., to inhibit, block, or reverse the activation, migration,proliferation, alteration of cellular function, and to preserve thenormal function of cells. The activity contemplated by the methodsdescribed herein includes both medical therapeutic and/or prophylactictreatment, as appropriate, and the compositions of the invention may beused to provide improvement in any of the conditions described. It isalso contemplated that the compositions described herein may beadministered to healthy subjects or individuals not exhibiting symptomsbut who may be at risk of developing a particular disorder. The specificdose of a compound administered according to this invention to obtaintherapeutic and/or prophylactic effects will, of course, be determinedby the particular circumstances surrounding the case, including, forexample, the compound administered, the route of administration, and thecondition being treated. However, it will be understood that the chosendosage ranges are not intended to limit the scope of the invention inany way. A therapeutically effective amount of compound of thisinvention is typically an amount such that when it is administered in aphysiologically tolerable excipient composition, it is sufficient toachieve an effective systemic concentration or local concentration inthe tissue.

The terms “treat,” “treated,” or “treating” as used herein refer to boththerapeutic treatment and prophylactic or preventative measures, whereinthe object is to prevent or slow down (lessen) an undesiredphysiological condition, disorder, or disease, or to obtain beneficialor desired clinical results. For the purposes of this invention,beneficial or desired results include, but are not limited to,alleviation of symptoms; diminishment of the extent of the condition,disorder, or disease; stabilization (i.e., not worsening) of the stateof the condition, disorder, or disease; delay in onset or slowing of theprogression of the condition, disorder, or disease; amelioration of thecondition, disorder, or disease state; and remission (whether partial ortotal), whether detectable or undetectable, or enhancement orimprovement of the condition, disorder, or disease. Treatment includesprolonging survival as compared to expected survival if not receivingtreatment.

Among its many embodiments the present invention provides a compound ofFormula I

or a pharmaceutically-acceptable salt thereof, wherein R is anitro-alcohol or a C₁-C₁₅ nitroalkenyl; R¹, R², R⁴, and R⁵ areindependently a —H or —CH₃; and R³ is selected from the group consistingof —H, —OH, —OBoc, —OCH₃, —OBn, —SH, —NO₂, —NH₂, —CN, a carbonyl, asulfonate, an amidino.

Also included in the family of compounds of Formula I are thestereoisomers thereof. Compounds of the present invention can possessone or more asymmetric carbon atoms and are thus capable of existing inthe form of optical isomers as well as in the form of racemic ornonracemic mixtures thereof. Accordingly, some of the compounds of thisinvention may be present in racemic mixtures which are also included inthis invention.

The optical isomers can be obtained by resolution of the racemicmixtures according to conventional processes, for example by formationof diastereoisomeric salts by treatment with an optically active baseand then separation of the mixture of diastereoisomers bycrystallization, followed by liberation of the optically active basesfrom these salts. Another method calls for chiral separation of theenantiomers with the use of a chiral chromatography column optimized tomaximize the separation of the enantiomers. Optimization of thechromatographic method of chiral resolution is routine for one ofordinary skill in the art. Yet another method for isolating opticalisomers is by distillation, crystallization or sublimation if a physicalproperty of the enantiomers is different. The optically active compoundsof Formula I can also be obtained by utilizing optically active startingmaterials. The isomers may be in the form of a free acid, a free base,an ester or a salt.

Also included in the family of compounds of Formula I and thestereoisomers are the pharmaceutically-acceptable salts thereof. Theterm “pharmaceutically-acceptable salts” embraces salts commonly used toform alkali metal salts and to form additional salts of free acids orfree bases. The nature of the salt is not critical, provided that it ispharmaceutically-acceptable. Suitable pharmaceutically-acceptable acidaddition salts of compounds of Formula I may prepared from an inorganicacid or from an organic acid. Examples of such inorganic acids arehydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric andphosphoric acid. Appropriate organic acids may include aliphatic,cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic andsulfonic classes of organic acids. Examples of such organic acidsinclude formic, acetic, propionic, succinic, glycolic, gluconic, lactic,malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic,aspartic, glutamic, benzoic, anthranilic, mesylic, salicylic,4-hydrobenzoic, phylacetic, mandelic, embonic, methanesulfonic,ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic,toluenesulfonic, sulfanilic, cyclohyexylaminosuflonic, stearic, algenic,P3-hydrobutyric, galactaric and galacturnoic acid. Suitablepharmaceutically-acceptable base addition salts of compounds of FormulaI include metallic salts, such as salts made from aluminum, calcium,lithium, magnesium, potassium, sodium and zinc, or salts made fromorganic bases including primary, secondary and tertiary amines,substituted amines including cyclic amines, such as caffeine, arginine,diethylamine, N-ethyl piperidine, histidine, glucamine, isopropylamine,lysine, morpholine, N-ethyl morpholine, piperazine, triethylamine,trimethylamine. All the listed salts of the corresponding compound ofthe invention may be prepared by conventional means known to one ofordinary skill in the art. One example of a conventional method of saltformation is by reacting the appropriate acid or base with the compoundsof Formula I at various mole ratios. Another method is by usingdifferent mole ratios of the appropriate acid or base in various solventsystems to control the concentration of the dissociated species of thecompounds of Formula I to maximize salt formation. The present inventionalso contemplates crystalline forms of the salts described herein.

Crystalline forms of the compounds of Formula I, may also include butare not limited to hydrates, solvates, and co-crystals. Crystallinesolvates include solvents including but not limited to the following:MeOH, EtOH, AcOH, EtOEt, AcOEt, acetone, DMSO, DMF, MeCN, CH₂Cl₂, CHCl₃,CCl₄, dioxane, THF, benzene, toluene, p-xylene, and hexane.

Crystalline hydrates and solvates may be stoichiometric as according tothe mole ratio of the water or organic solvent molecule to the compoundor salt thereof. The crystalline hydrate may also be non-stoichiometricdepending on the conditions of the unit cell which result in athermodynamically or kinetically stable crystal. Crystalline salts andco-crystals may also be stoichiometric or non-stoichiometric for reasonsstated above. One of skill in the art of crystallography understandsthat the components in the unit cell of a crystal may or may not bestoichiometric depending on the conditions which stabilize the crystal.

Administration and Compositions

The compounds of Formula I can be administered to a patient

The compounds and pharmaceutically-acceptable salts thereof can beadministered by means that produces contact of the active agent with theagent's site of action. They can be administered by conventional meansavailable for use in conjunction with pharmaceuticals in a dosage rangeof 0.001 to 1000 mg/kg of mammal (e.g. human) body weight per day in asingle dose or in divided doses. One dosage range is 0.01 to 500 mg/kgbody weight per day orally in a single dose or in divided doses.Administration can be delivered as individual therapeutic agents or in acombination of therapeutic agents. They can be administered alone, buttypically are administered with a pharmaceutically acceptable excipientselected on the basis of the chosen route of administration and standardpharmaceutical practice.

Compounds can be administered by one or more ways. For example, thefollowing routes may be utilized: oral, parenteral (includingsubcutaneous injections, intravenous, intramuscular, intrasternalinjection or infusion techniques), inhalation, buccal, sublingual, orrectal, in the form of a unit dosage of a pharmaceutical compositioncontaining an effective amount of the compound and optionally incombination with one or more pharmaceutically-acceptable excipients suchas stabilizers, anti-oxidants, lubricants, bulking agents, fillers,carriers, adjuvants, vehicles, diluents and other readily knownexcipients in standard pharmaceutical practice.

Liquid preparations suitable for oral administration (e.g. suspensions,syrups, elixirs and other similar liquids) can employ media such aswater, glycols, oils, alcohols, and the like. Solid preparationssuitable for oral administration (e.g. powders, pills, capsules andtablets) can employ solid excipients such as starches, sugars, kaolin,lubricants, binders, disintegrating agents, antioxidants and the like.

Parenteral compositions typically employ sterile water as a carrier andoptionally other ingredients, such as solubility aids. Injectablesolutions can be prepared, for example, using a carrier comprising asaline solution, a glucose solution or a solution containing a mixtureof saline and glucose. Further guidance for methods suitable for use inpreparing pharmaceutical compositions is provided in Remington: TheScience and Practice of Pharmacy, 21^(st) edition (Lippincott Williams &Wilkins, 2006).

Therapeutic compounds can be administered orally in a dosage range ofabout 0.001 to 1000 mg/kg of mammal (e.g. human) body weight per day ina single dose or in divided doses. One dosage range is about 0.01 to 500mg/kg body weight per day orally in a single dose or in divided doses.For oral administration, the compositions can be provided in the form oftablets or capsules containing about 1.0 to 500 mg of the activeingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150,200, 250, 300, 400, 500, and 750 mg of the active ingredient for thesymptomatic adjustment of the dosage to the patient to be treated. Thespecific dose level and frequency of dosage for any particular patientmay be varied and will depend upon a variety of factors including theactivity of the specific compound employed, the metabolic stability andlength of action of that compound, the age, body weight, general health,sex, diet, mode and time of administration, rate of excretion, drugcombination, the severity of the particular condition, and the hostundergoing therapy. In view of the factors affecting the specific doselevel and frequency it is contemplated that the dose frequency can rangefrom multiple doses daily to monthly dosages. The preferred dosefrequency ranges from twice a day to every two weeks. A more preferreddose frequency ranges from twice a day to weekly. A most preferred dosefrequency ranges from twice a day to twice a week.

In the methods of various embodiments, pharmaceutical compositionsincluding the active agent can be administered to a subject in an“effective amount.” An effective amount may be any amount that providesa beneficial effect to the patient, and in particular embodiments, theeffective amount is an amount that may 1) prevent the subject fromexperiencing one or more adverse effects associated with a administeredagents, such as those used to diagnose, identify, and treat medicalconditions, 2) reduce side effects experienced by the subject as aresult of a medical therapy or reduce the side effects known to resultfrom such therapies, and/or 3) eliminate side effects resulting from amedical treatment experienced by the subject prior to administration ofthe active agent or eliminate the side effects known to result from suchtreatment.

Pharmaceutical formulations containing the compounds of the inventionand a suitable carrier can be in various forms including, but notlimited to, solids, solutions, powders, fluid emulsions, fluidsuspensions, semi-solids, and dry powders including an effective amountof an the active agent of the invention. It is also known in the artthat the active ingredients can be contained in such formulations withpharmaceutically acceptable diluents, fillers, disintegrants, binders,lubricants, surfactants, hydrophobic vehicles, water soluble vehicles,emulsifiers, buffers, humectants, moisturizers, solubilizers,antioxidants, preservatives and the like. The means and methods foradministration are known in the art and an artisan can refer to variouspharmacologic references for guidance. For example, ModernPharmaceutics, Banker & Rhodes, Marcel Dekker, Inc. (1979); and Goodman& Gilman's, The Pharmaceutical Basis of Therapeutics, 6th Edition,MacMillan Publishing Co., New York (1980) both of which are herebyincorporated by reference in their entireties can be consulted.

Other embodiments of the invention include the active agent prepared asdescribed above which are formulated as a solid dosage form for oraladministration including capsules, tablets, pills, powders, andgranules. In such embodiments, the active compound may be admixed withone or more inert diluent such as sucrose, lactose, or starch. Suchdosage forms may also comprise, as in normal practice, additionalsubstances other than inert diluents, e.g., lubricating agents such asmagnesium stearate. In the case of capsules, tablets, and pills, thedosage forms may also comprise buffering agents and can additionally beprepared with enteric coatings.

In another exemplary embodiment, an oily preparation of an active agentprepared as described above may be lyophilized to form a solid that maybe mixed with one or more pharmaceutically acceptable excipient, carrieror diluent to form a tablet, and in yet another embodiment, the activeagent may be crystallized to from a solid which may be combined with apharmaceutically acceptable excipient, carrier or diluent to form atablet.

The means and methods for tableting are known in the art and one ofordinary skill in the art can refer to various references for guidance.For example, Pharmaceutical Manufacturing Handbook: Production andProcesses, Shayne Cox Gad, John Wiley & Sons, Inc., Hoboken, N.J.(2008), which is hereby incorporated by reference in its entirety, canbe consulted.

Further embodiments which may be useful for oral administration of theactive agent include liquid dosage forms. In such embodiments, a liquiddosage may include a pharmaceutically acceptable emulsion, solution,suspension, syrup, and elixir containing inert diluents commonly used inthe art, such as water. Such compositions may also comprise adjuvants,such as wetting agents, emulsifying and suspending agents, andsweetening, flavoring, and perfuming agents. Thus, for example, thecompounds can be formulated with suitable polymeric or hydrophobicmaterials (for example, as an emulsion in an acceptable oil) or ionexchange resins, or as sparingly soluble derivatives, for example, as asparingly soluble salt.

Other suitable diluents include, but are not limited to those describedbelow:

Vegetable oil: The vegetable oil may be hydrogenated or unhydrogenated.Suitable vegetable oils include, but are not limited to castor oil,hydrogenated castor oil, sesame oil, corn oil, peanut oil, olive oil,sunflower oil, safflower oil, soybean oil, benzyl benzoate, sesame oil,cottonseed oil, and palm oil. Other suitable vegetable oils includecommercially available synthetic oils such as, but not limited to,Miglyol™ 810 and 812 (available from Dynamit Nobel Chemicals, Sweden)Neobee™ M5 (available from Drew Chemical Corp.), Alofine™ (availablefrom Jarchem Industries), the Lubritab™ series (available from JRSPharma), the Sterotex™ (available from Abitec Corp.), Softisan™ 154(available from Sasol), Croduret™ (available from Croda), Fancol™(available from the Fanning Corp.), Cutina™ HR (available from Cognis),Simulsol™ (available from CJ Petrow), EmCon™ CO (available from AmisolCo.), Lipvol™ CO, SES, and HS-K (available from Lipo), and Sterotex™ HM(available from Abitec Corp.). Other suitable vegetable oils, includingsesame, castor, corn, and cottonseed oils, include those listed in R. C.Rowe and P. J. Shesky, Handbook of Pharmaceutical Excipients, (2006),5th ed., which is incorporated herein by reference in its entirety.Suitable polyethoxylated vegetable oils, include but are not limited to,Cremaphor™ EL or RH series (available from BASF), Emulphor™ EL-719(available from Stepan products), and Emulphor™ EL-620P (available fromGAF).

Mineral oils: As used herein, the term “mineral oil” refers to bothunrefined and refined (light) mineral oil. Suitable mineral oilsinclude, but are not limited to, the Avatech™ grades (available fromAvatar Corp.), Drakeol™ grades (available from Penreco), Sirius™ grades(available from Shell), and the Citation™ grades (available from AvaterCorp.).

Castor oils: As used herein, the term “castor oil,” refers to a compoundformed from the ethoxylation of castor oil, wherein at least one chainof polyethylene glycol is covalently bound to the castor oil. The castoroil may be hydrogenated or unhydrogenated. Synonyms for polyethoxylatedcastor oil include, but are not limited to polyoxyl castor oil,hydrogenated polyoxyl castor oil, mcrogolglyceroli ricinoleas,macrogolglyceroli hydroxystearas, polyoxyl 35 castor oil, and polyoxyl40 hydrogenated castor oil. Suitable polyethoxylated castor oilsinclude, but are not limited to, the Nikkol™ HCO series (available fromNikko Chemicals Co. Ltd.), such as Nikkol HCO-30, HC-40, HC-50, andHC-60 (polyethylene glycol-30 hydrogenated castor oil, polyethyleneglycol-40 hydrogenated castor oil, polyethylene glycol-50 hydrogenatedcastor oil, and polyethylene glycol-60 hydrogenated castor oil,Emulphor™ EL-719 (castor oil 40 mole-ethoxylate, available from StepanProducts), the Cremophore™ series (available from BASF), which includesCremophore RH40, RH60, and EL35 (polyethylene glycol-40 hydrogenatedcastor oil, polyethylene glycol-60 hydrogenated castor oil, andpolyethylene glycol-35 hydrogenated castor oil, respectively), and theEmulgin® RO and HRE series (available from Cognis PharmaLine). Othersuitable polyoxyethylene castor oil derivatives include those listed inR. C. Rowe and P. J. Shesky, Handbook of Pharmaceutical Excipients,(2006), 5th ed., which is incorporated herein by reference in itsentirety.

Sterol: As used herein, the term “sterol” refers to a compound, ormixture of compounds, derived from the ethoxylation of sterol molecule.Suitable polyethoyxlated sterols include, but are not limited to, PEG-24cholesterol ether, Solulan™ C-24 (available from Amerchol); PEG-30cholestanol, Nikkol™ DHC (available from Nikko); Phytosterol, GENEROL™series (available from Henkel); PEG-25 phyto sterol, Nikkol™ BPSH-25(available from Nikko); PEG-5 soya sterol, Nikkol™ BPS-5 (available fromNikko); PEG-10 soya sterol, Nikkol™ BPS-10 (available from Nikko);PEG-20 soya sterol, Nikkol™ BPS-20 (available from Nikko); and PEG-30soya sterol, Nikkol™ BPS-30 (available from Nikko).

Polyethylene glycol: As used herein, the term “polyethylene glycol” or“PEG” refers to a polymer containing ethylene glycol monomer units offormula —O—CH₂—CH₂—. Suitable polyethylene glycols may have a freehydroxyl group at each end of the polymer molecule, or may have one ormore hydroxyl groups etherified with a lower alkyl, e.g., a methylgroup. Also suitable are derivatives of polyethylene glycols havingesterifiable carboxy groups. Polyethylene glycols useful in the presentinvention can be polymers of any chain length or molecular weight, andcan include branching. In some embodiments, the average molecular weightof the polyethylene glycol is from about 200 to about 9000. In someembodiments, the average molecular weight of the polyethylene glycol isfrom about 200 to about 5000. In some embodiments, the average molecularweight of the polyethylene glycol is from about 200 to about 900. Insome embodiments, the average molecular weight of the polyethyleneglycol is about 400. Suitable polyethylene glycols include, but are notlimited to polyethylene glycol-200, polyethylene glycol-300,polyethylene glycol-400, polyethylene glycol-600, and polyethyleneglycol-900. The number following the dash in the name refers to theaverage molecular weight of the polymer. In some embodiments, thepolyethylene glycol is polyethylene glycol-400. Suitable polyethyleneglycols include, but are not limited to the Carbowax™ and Carbowax™Sentry series (available from Dow), the Lipoxol™ series (available fromBrenntag), the Lutrol™ series (available from BASF), and the Pluriol™series (available from BASF).

Propylene glycol fatty acid ester: As used herein, the term “propyleneglycol fatty acid ester” refers to an monoether or diester, or mixturesthereof, formed between propylene glycol or polypropylene glycol and afatty acid. In some embodiments, the monoester or diester has about 1 toabout 200 oxypropylene units. In some embodiments, the polypropyleneglycol portion of the molecule has about 2 to about 100 oxypropyleneunits. In some embodiments, the monoester or diester has about 4 toabout 50 oxypropylene units. In some embodiments, the monoester ordiester has about 4 to about 30 oxypropylene units. Suitable propyleneglycol fatty acid esters include, but are not limited to, propyleneglycol laurates: Lauroglycol™ FCC and 90 (available from Gattefosse);propylene glycol caprylates: Capryol™ PGMC and 90 (available fromGatefosse); and propylene glycol dicaprylocaprates: Labrafac™ PG(available from Gatefosse).

Stearoyl macrogol glyceride: Stearoyl macrogol glyceride refers to apolyglycolized glyceride synthesized predominately from stearic acid orfrom compounds derived predominately from stearic acid, although otherfatty acids or compounds derived from other fatty acids may used in thesynthesis as well. Suitable stearoyl macrogol glycerides include, butare not limited to, Gelucire® 50/13 (available from Gattefosse).

In some embodiments, the diluent component comprises one or more ofmannitol, lactose, sucrose, maltodextrin, sorbitol, xylitol, powderedcellulose, microcrystalline cellulose, carboxymethylcellulose,carboxyethylcellulose, methylcellulose, ethylcellulose,hydroxyethylcellulose, methylhydroxyethylcellulose, starch, sodiumstarch glycolate, pregelatinized starch, a calcium phosphate, a metalcarbonate, a metal oxide, or a metal aluminosilicate.

Exemplary excipients or carriers for use in solid and/or liquid dosageforms include, but are not limited to:

Sorbitol: Suitable sorbitols include, but are not limited to,PharmSorbidex E420 (available from Cargill), Liponic 70-NC and 76-NC(available from Lipo Chemical), Neosorb (available from Roquette),Partech SI (available from Merck), and Sorbogem (available from SPIPolyols).

Starch, sodium starch glycolate, and pregelatinized starch include, butare not limited to, those described in R. C. Rowe and P. J. Shesky,Handbook of Pharmaceutical Excipients, (2006), 5th ed., which isincorporated herein by reference in its entirety.

Disintegrant: The disintegrant may include one or more of croscarmellosesodium, carmellose calcium, crospovidone, alginic acid, sodium alginate,potassium alginate, calcium alginate, an ion exchange resin, aneffervescent system based on food acids and an alkaline carbonatecomponent, clay, talc, starch, pregelatinized starch, sodium starchglycolate, cellulose floc, carboxymethylcellulose,hydroxypropylcellulose, calcium silicate, a metal carbonate, sodiumbicarbonate, calcium citrate, or calcium phosphate.

Still further embodiments of the invention include the active agentadministered in combination with other active such as, for example,adjuvants, protease inhibitors, or other compatible drugs or compoundswhere such combination is seen to be desirable or advantageous inachieving the desired effects of the methods described herein.

Other embodiments of the present invention include a pharmaceuticalcomposition comprising an effective amount of the active agent and oneor more pharmaceutically acceptable excipient. Other embodiments includea pharmaceutical composition comprising an effective amount ofpharmaceutically-acceptable salts of the active agent. Other embodimentsinclude a pharmaceutical composition comprising an effective amount ofpharmaceutically-acceptable salts of active agent and apharmaceutically-acceptable excipient.

In yet other embodiments, the active agent may be combined with one ormore secondary agents.

General Synthetic Procedures

The general synthetic routes by which the derivatives of trolox areobtained are shown in Schemes 1, 2 and 3.

Scheme 1 illustrates preparation of nitrated trolox derivatives withvinyl nitro groups of at the trolox end of the hydrocarbon chain. Thistype of vinyl nitro is also referred to as the initial vinyl nitro groupherein. In Scheme 1, the methyl ester starting material can be formed byreacting commercially available Trolox (Sigma-Aldrich) with methanol andan acid such as sulfuric acid. The reaction proceeds with the attachmentof a protective group such as tert-butyloxycarbonyl (Boc). The methylester is then reduced to a primary alcohol and subsequently oxidized toproduce the aldehyde derivative. The beta-nitro alcohol intermediate isproduced via condensation of the aldehyde derivative with a primarynitroalkane, wherein R′ is hydrogen or a C₁-C₁₁ carbon, in the presenceof a base (Henry reaction). The base used in the Henry reaction can beDBU, imidazole, or any catalytic base known to a person of ordinaryskill in the art. Dehydration of the beta-nitro alcohol followed by Bocdeprotection produces the desired product.

This scheme represents a proposed synthesis for the trolox derivativescontaining a vinyl nitro group at the C_(n-1) carbon. This vinyl nitrois also referred to as the terminal nitro vinyl group herein. From thealdehyde derivative produced in the manner shown in Scheme 1, a Wittigreaction with LIHMDS as the base and a hydroxyl-phosphonium salt(prepared as described elsewhere) with the appropriate carbon length,render the alkene with a terminal hydroxyl group. After alkene reductionwith H₂ and Pd/C, alcohol oxidation to aldehyde, nitroaldolic reactionwith nitromethane using ammonium acetate and Boc deprotection, renderthe desire products.

Scheme 3 illustrates a general reaction for preparing embodiments withthe scope of contemplated compounds wherein the vinyl nitro group isdisposed within the hydrocarbon tail otherwise called an intermediatevinyl nitro group herein.

From tert-butyl 2-formyl-2,5,7,8-tetramethylchroman-6-yl carbonate,synthesized as previously described (the intermediate from the synthesisof compounds with the nitro vinyl group at the beginning of hydrocarbonchain nearest the chromanol base structure).ω-Hydroxyalkyltriphenylphosphonium bromides were synthesized asdescribed in literature (Lei, H., and Atkinson, J. Synthesis of phytyl-and chroman-derivatized photoaffinity labels based on alpha-tocopherol.J Org Chem 2000, 65:2560-2567).

EXAMPLES

The following examples contain detailed methods of preparing compoundsof Formula I. These detailed descriptions serve to exemplify the abovegeneral synthetic schemes which form part of the invention. Thesedetailed descriptions are presented for illustrative purposes only andare not intended as a restriction on the scope of the invention. Allparts are by weight and temperatures are in Degrees Celsius unlessotherwise indicated. All compounds showed NMR spectra consistent withtheir assigned structures.

Example 1: (±)-2,5,7,8-tetramethyl-2-[(E)-2-nitrovinyl]chroman-6-ol(NAT×0)

Step 1. Preparation of the Protected Intermediate 2 (methyl6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethylchroman-2-carboxylate)

To a methyl ester 1 (1.5 g, 5.70 mmol) solution in DCM under N₂ flux,di-tert-butyl dicarbonate (1.1 g, 5.11 mmol) and a nucleophiliccatalyst, DMAP (0.07 g, 0.57 mmol), were added. After 2 hours ofagitation at room temperature, reaction was stopped, solvent wasevaporated, ethyl acetate was added (20 mL) and then washed with HCl 10%(50 mL) and saturated NaHCO₃ (50 mL). The resulting organic layers weredried with Na₂SO₄, filtered and the solvent was evaporated under reducedpressure. Purification by column chromatography in SiO₂ and hexane:ethyl acetate 7:3 as mobile phase rendered the desired product as awhite solid (1.3 g, 65%). ¹H NMR (400 MHz, CDCl₃): δ 3.70 (s, 3H), 2.69(m, 1H), 2.53 (m, 1H), 2.45 (m, 1H), 2.18 (s, 3H), 2.11 (s, 3H), 2.02(s, 3H), 1.88 (m, 1H), 1.62 (s, 3H), 1.57 (s, 9H).

Step 2. Preparation of 3(6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethylchroman-2-methanol)

To a suspension of a reducing agent, LiAlH₄ (1.8 mmol, 0.07 g), in dryTHF (2 mL) cooled to 0° C. in a water-salt bath under nitrogenatmosphere, 2 (1.6 mmol, 0.6 g) dissolved in 4 mL of dry THF was addeddropwise. The reaction mixture was stirred at 0° C. for 45 min andpoured into a saturated aqueous solution of NH₄Cl (6 mL) and extractedwith EtOAc (3×10 mL). The combined organic layers were washed with water(1×10 mL), brine (1×10 mL), dried (Na₂SO₄), filtered and the solvent wasevaporated under reduced pressure, to give a white solid (0.50 g, 94%).No further purification was required. ¹H NMR (300 MHz, CDCl₃): δ 3.70(m, 2H, 4H), 2.70 (m, 2H), 2.11 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H),2.00 (m, 1H), 1.91 (t, 1H), 1.76 (m, 1H), 1.58 (s, 9H), 1.25 (s, 3H).

Step 3. Preparation of 4(6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde)

To a solution of 3 (1.5 mmol, 0.50 g) an oxidizing catalyst, TEMPO (0.32mmol, 0.047 g), in acetone, and (diacetoxyiodo)benzene (2.0 mmol, 0.65g) was added. After 20 h of stirring at room temperature the reactionmixture was poured into water (10 mL) and extracted with diethyl ether(4×10 mL). The organic layers were dried with Na₂SO₄, filtered and thesolvent was evaporated under reduced pressure. The liquid residue wasloaded onto a silica gel flash column and eluted with hexane: ethylacetate 95:5 to afford a white solid (0.16 g, 32%). ¹H NMR (400 MHz,CDCl₃): δ 9.65 (s, 1H), 2.67 (m, 2H), 2.31 (m, 1H), 2.22 (s, 3H), 2.13(s, 3H), 2.03 (s, 3H), 1.87 (m, 1H), 1.58 (s, 9H), 1.42 (s, 3H).

Step 4. Preparation of 5(6-((tert-butoxycarbonyl)oxy)-2-(1-hydroxy-2-nitroethyl)-2,5,7,8-tetramethylchroman)

To a solution of imidazole (1.3 mmol, 0.09 g) in nitromethane (3.5 mL,65 mmol), 4 (0.65 mmol, 0.16 g) was added. After 2 days of stirring atroom temperature, solvent was evaporated under reduced pressure and thecrude product was poured into brine and extracted with ethyl acetate.The organic layers were dried with Na₂SO₄, filtered and the solvent wasevaporated under reduced pressure. The residue was loaded onto a silicagel flash column and eluted with hexane: ethyl acetate 8:2 to afford awhite solid (0.12 g, 60%). ¹H NMR (400 MHz, CDCl₃): δ 4.81 (m, 1H), 4.61(m, 1H), 4.44 (m, 1H), 2.84 (d, J=4 Hz, 1H), 2.74 (m, 2H), 2.11 (s, 3H),2.09 (s, 3H), 2.07 (s, 3H), 1.99 (m, 2H), 1.58 (s, 9H), 1.26 (s, 3H).¹³C NMR (400 MHz, CDCl₃): δ 77, 73, 28, 27, 20, 19, 13.

Step 5. Preparation of 6(2-(1-acetoxy-2-nitroethyl)-6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethylchroman)

A solution of 5 (0.092 mmol, 0.036 mg) in acetic anhydride (2.9 mmol,0.28 mL) and catalytic amount of a sulphonic acid, p-toluensulphonicacid, was kept in agitation for 16 h under N₂ flow. Then, water (10 mL)was added and agitation continued for 10 minutes more to remove aceticanhydride excess as acetic acid. Product was extracted with diethylether (4 mL) and the organic layer was washed with water (3×5 mL). Theorganic layer was dried with Na₂SO₄, filtered and the solvent wasevaporated under reduced pressure to obtain a white solid (0.037 g,93%). ¹H NMR (400 MHz, CDCl₃): δ 5.85 (m, 1H), 4.88 (m, 1H), 4.74 (m,1H), 2.80 (m, 1H), 2.65 (m, 1H), 2.14 (s, 3H), 2.10 (s, 3H), 2.08 (s,3H), 2.06 (s, 3H), 1.90 (m, 2H), 1.57 (s, 9H), 1.29 (s, 3H).

Step 6. Preparation of 7(6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethyl-2-[(E)2-nitrovinyl]chroman)

Reactants were dissolved in dry toluene and the mixture was heated at110° C. for 2 h. After the reaction mixture reached ambient temperature,it was poured into brine (10 mL) and extracted with diethyl ether (3×5mL) to obtain a yellow solid (0.03 g, 94%) with no further purification.¹H NMR (400 MHz, CDCl₃): δ 7.28 (d, J=12 Hz, 1H), 7.02 (d, J=12 Hz, 1H),2.76 (m, 1H), 2.57 (m, 1H), 2.17 (s, 3H), 2.13 (s, 3H), 2.07 (s, 3H),2.05 (m, 2H), 1.57 (s, 9H), 1.28 (s, 3H). ¹³C-NMR (400 MHz, CDCl₃): δ152.1, 147.9, 144.6, 141.8, 139.6, 127.9, 125.6, 122.8, 116.7, 82.96,74.06, 31.44, 30.33, 29.72, 27.69, 25.87, 20.51, 12.75, 11.91, 11.86. MS(EI⁺): m/z (%): 377 (M⁺, 6), 277 (100), 164 (55).

Step 7. Preparation of NAT×0

To a solution of 7 (0.03 g, 0.08 mmol) in DCM, TFA (0.135 mL, 1.75 mmol)was added and the reaction was stirred for 2 h at room temperature.Then, the reaction mixture was washed with NaHCO₃ sat. (5 mL) and brine(5 mL). The organic layer was dried with Na₂SO₄, filtered and thesolvent was evaporated under reduced pressure. The residue was loadedonto a silica gel flash column and eluted with hexane: ethyl acetate 8:2to afford a yellow solid (0.066 g, 30%). ¹H NMR (400 MHz, CDCl₃): δ 7.28(d, J=13.6 Hz, 1H), 6.99 (d, J=13.2 Hz, 1H), 4.31 (s, 1H), 2.77 (m, 1H),2.56 (m, 1H), 2.20 (s, 3H), 2.19 (s, 3H), 2.11 (s, 3H), 2.09 (m, 1H),2.00 (m, 1H), 1.53 (s, 3H). ¹³C-NMR (400 MHz, CDCl₃): δ 145.5, 144.8,144.2, 139.6, 122.3, 121.7, 118.6, 116.6, 73.71, 31.80, 26.04, 20.75,12.23, 11.85, 11.32. MS (EI⁺): m/z (%): 277 (M⁺, 71), 164 (100), 136(29), 121 (28).

Example 2:(+)-2,5,7,8-tetramethyl-2-[(E)-2-nitropent-1-en-1-yl]chroman-6-ol(NAT×5)

Steps 1-3 of Example 1 are repeated to prepare 4(6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde).

Step 4. Preparation of tert-butyl(2,5,7,8-tetramethyl-2-[(E)-2-nitropent-1-en-1-yl]chroman-6-yl)carbonate

A mixture of 1-nitrobutane (0.023 g, 0.22 mmol), aldehyde 4 (0.075 g,0.22 mmol) and DBU (0.1 mL, 0.022 mmol) in acetonitrile (1 mL) wasstirred at room temperature for 24 h. The solvent was removed underreduced pressure and the residue was loaded onto a silica gel column(SiO₂, Hexane: Ethyl acetate 85:15) to afford the nitrohydroxy productas a diasteromeric mixture (white solid 0.075 g, 81%). MS (EI⁺): m/z(%): 437 (M⁺, 4), 337 (22), 234 (39), 205 (100), 149 (21), 57 (94).HRMS: m/z [M^(+]) calcd. for C₂₃H₃₅NO₇: 437.2414, found: 437.2421.

To nitrohydroxy intermediate (0.07 g, 0.16 mmol) in dry DCM (3 mL),methanesulfonyl chloride (0.037 g, 0.32 mmol) and triethylamine (0.058mL, 0.42 mmol) were added in an ice-water bath. After 2 h, completeformation of mesyl derivatives (as diasteromic mixture) was observed.Then DBU (0.06 g, 0.4 mmol) was added and reaction was stirredovernight. Water was added (20 mL) and compound was extracted with ethylacetate (3×5 mL), dried with Na₂SO₄, filtered and solvent removed underreduced pressure. The residue was loaded onto a silica gel column (SiO₂,Hexane: Ethyl acetate 85:15) to afford the desire product as a yellowoil (0.046 g, 69%). ¹H-NMR (CDCl₃, 500 MHz): δ=6.93 (s, 1H); 2.67 (t,J=10 Hz, 2H), 2.60 (m, 1H), 2.53 (m, 1H), 2.07 (s, 3H), 2.02 (s, 3H),1.97 (m, 1H), 1.95 (s, 3H), 1.84 (m, 1H), 1.47 (s, 9H), 1.46 (s, 3H),1.40 (m, 1H), 1.20 (m, 1H), 0.82 (t, J=10 Hz, 3H). ¹³C-NMR (CDCl₃, 500MHz): δ 153.1, 152.1, 148.4, 141.7, 137.4, 128.2, 125.7, 122.7, 117.2,82.88, 74.66, 32.90, 28.22, 27.62, 26.41, 21.62, 20.77, 13.93, 12.77,12.08, 11.91. MS (EI⁺): m/z (%): 419 (M⁺, 2.04), 319 (29.04), 164.08(19.62), 57.07 (100). HRMS: m/z [M⁺] calcd. for C₂₃H₃₃NO₆: 419.2308,found: 419.2308.

Step 5. Preparation of NAT×5

To a solution of tert-butyl(2,5,7,8-tetramethyl-2-[(E)-2-nitropent-1-en-1-yl)chroman-6-yl)carbonate (0.02 g, 0.048 mmol) in DCM (0.8 mL), TFA (0.081 mL, 1.05mmol) was added and was stirred for 2 h at room temperature. Then, thereaction mixture was washed with NaHCO₃ sat. (10 mL) and brine (10 mL).The organic layer was dried with Na₂SO₄, filtered and the solvent wasevaporated under reduced pressure. The residue was loaded onto a silicagel flash column (SiO₂, hexane: ethyl acetate 9:1) to afford a yellowoil (0.014 g, 93%). ¹H-NMR (CDCl₃, 400 MHz): δ=6.93 (s, 1H), 4.19 (s,1H, OH), 2.67 (t, J=8 Hz, 2H), 2.61 (m, 1H), 2.55 (m, 1H), 2.09 (s, 6H),2.02 (s, 3H), 2.00 (m, 1H), 1.84 (m, 1H), 1.47 (s, 3H), 1.38 (m, 1H),1.18 (m, 1H), 0.83 (t, J=8 Hz, 3H). MS (EI⁺): m/z (%): 319 (M⁺, 74), 164(100), 121 (19). HRMS: m/z [M⁺] calcd. for C₁₈H₂₅NO₄: 319.1784, found:319.1761.

Example 3:(+)-2,5,7,8-tetramethyl-2-[(E)-2-nitrooct-1-en-1-yl]chroman-6-ol (NAT×8)

Steps 1-3 of Example 1 are repeated to prepare 4(6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde).

Step 4. Preparation of tert-butyl(2,5,7,8-tetramethyl-2-[(E)-2-nitrooct-1-en-1-yl]chroman-6-yl) carbonate

A mixture of 1-nitroheptane (0.087 g, 0.60 mmol), aldehyde 4 (0.2 g, 0.6mmol) and DBU (0.1 mL, 0.06 mmol) in acetonitrile (2 mL) was stirred atroom temperature for 24 h. The solvent was removed under reducedpressure and the residue was loaded onto a silica gel column (SiO2,Hexane: Ethyl acetate 85:15) to afford the nitrohydroxy product as adiasteromeric mixture (yellow oil, 0.214 g, 76%). MS (EI⁺): m/z (%): 479(M+, 1.4), 379 (18), 234 (44), 205 (99), 57 (100). HRMS: m/z [M+] calcd.for C₂₆H₄₁NO₇: 479.2883, found: 479.2867.

To nitrohydroxy intermediate (0.2 g, 0.42 mmol) in dry DCM (5 mL) at 0°C., methanesulfonyl chloride (0.048 g, 0.42 mmol) and triethylamine(0.15 mL, 1.1 mmol) were added. After 2 h, complete formation of mesylderivatives (as diasteromic mixture) was observed. Then DBU (0.16 g, 1.0mmol) was added and reaction was stirred overnight. Water was added (15mL) and compound was extracted with ethyl acetate (3×5 mL), dried withNa₂SO₄, filtered and solvent removed under reduced pressure. The residuewas loaded onto a silica gel column (SiO₂, Hexane: Ethyl acetate 85:15)to afford the desire product as a yellow oil (0.09 g, 47%). ¹H-NMR(CDCl₃, 500 MHz): δ=6.91 (s, 1H), 2.69 (t, J=10.2 Hz, 2H), 2.60 (m, 1H),2.54 (m, 1H), 2.07 (s, 3H), 2.01 (s, 3H), 1.99 (m, 1H), 1.95 (s, 3H),1.83 (m, 1H), 1.48 (s, 9H), 1.47 (s, 3H), 1.35 (m, 1H), 1.19 (m, 6H),1.06 (m, 1H), 0.81 (t, J=10.2 Hz, 3H). ¹³C— NMR (CDCl₃, 500 MHz): δ153.9, 152.1, 148.4, 141.7, 137.1, 128.2, 125.7, 122.6, 117.2, 82.85,74.67, 32.97, 31.52, 29.39, 28.28, 27.71 (2C), 26.51, 22.56, 21.04,14.04, 12.73, 12.08, 11.90. MS (EI⁺): m/z (%): 461 (M⁺, 5.50), 361(72.10), 164.08 (30.36), 57.07 (100). HRMS: m/z [M⁺] calcd. forC₂₆H₃₉NO₆: 461.2777, found: 461.2763.

Step 5. Preparation of NAT×8

Example 4:(+)-2,5,7,8-tetramethyl-2-[(E)-2-nitrotridec-1-en-1-yl]chroman-6-ol(NAT×13)

Steps 1-3 of Example 1 are repeated to prepare 4(6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde).

Step 4. Preparation of tert-butyl(2,5,7,8-tetramethyl-2-[(E)-2-nitrotridec-1-en-1-yl)chroman-6-yl)carbonate

A mixture of 1-nitrododecane (0.13 g, 0.60 mmol), aldehyde 4 (0.2 g, 0.6mmol) and DBU (0.1 mL, 0.06 mmol) in acetonitrile (2 mL) was stirred atroom temperature for 24 h. The solvent was removed under reducedpressure and the residue was loaded onto a silica gel column (SiO₂,Hexane: Ethyl acetate 85:15) to afford the nitrohydroxy product as adiasteromeric mixture (yellow oil, 0.14 g, 42%). MS (EI⁺): m/z (%): 449(6), 234 (27), 205 (61), 57 (100).

To nitrohydroxy intermediate (0.14 g, 0.26 mmol) in dry DCM (3 mL) at 0°C., methanesulfonyl chloride (0.030 g, 0.26 mmol) and triethylamine(0.068 mL, 0.7 mmol) were added. After 2 h, complete formation of mesylderivatives (as diasteromic mixture) was observed. Then DBU (0.1 g, 0.65mmol) was added and reaction was stirred overnight. Water was added (15mL) and compound was extracted with ethyl acetate (3×5 mL), dried withNa₂SO₄, filtered and solvent removed under reduced pressure. The residuewas loaded onto a silica gel column (SiO₂, Hexane: Ethyl acetate 85:15)to afford the desire product as a yellow oil (0.06 g, 44%). ¹H-NMR(CDCl₃, 500 MHz): δ=6.91 (s, 1H), 2.69 (t, J=8.1 Hz, 2H), 2.60 (m, 1H),2.55 (m, 1H), 2.07 (s, 3H), 2.01 (s, 3H), 1.97 (m, 1H), 1.96 (s, 3H),1.83 (m, 1H), 1.47 (s, 9H), 1.46 (s, 3H), 1.31 (m, 1H), 1.18 (m, 16H),1.08 (m, 1H), 0.82 (t, J=8.1 Hz, 3H). 13C-NMR (CDCl₃, 500 MHz): δ 154.0,152.1, 148.4, 141.7, 137.1, 127.8, 125.7, 122.7, 117.2, 82.84, 74.64,32.96, 31.92, 31.60, 29.72, 29.63, 29.62, 29.59, 29.55, 29.34, 28.32,27.70, 26.50, 22.70, 21.03, 14.12, 12.73, 12.08, 11.89. MS (EI⁺): m/z(%): 531 (M⁺, 2.11), 431 (100), 164 (36), 57 (98). HRMS: m/z [M⁺] calcd.for C₃₁H₄₉NO₆: 531.3560, found: 531.3588.

Step 5. Preparation of NAT×13

To a solution of tert-butyl(2,5,7,8-tetramethyl-2-(2-nitrotridec-1-en-1-yl)chroman-6-yl) carbonate(0.02 g, 0.038 mmol) in DCM (0.64 mL), TFA (0.064 mL, 0.83 mmol) wasadded and was agitated for 2 h at room temperature. Then, reactionmixture was washed with NaHCO₃ sat. (10 mL) and brine (10 mL). Theorganic layer was dried with Na₂SO₄, filtered and the solvent wasevaporated under reduced pressure. The residue was loaded onto a silicagel flash column (SiO₂, hexane: ethyl acetate 85:15) to afford a yellowoil (0.01 g, 63%). ¹H-NMR (CDCl₃, 400 MHz): δ=6.98 (s, 1H), 4.23 (s,1H), 2.75 (m, 2H), 2.68 (m, 1H), 2.63 (m, 1H), 2.16 (s, 3H), 2.15 (s,3H), 2.10 (s, 3H), 2.06 (m, 1H), 1.91 (m, 1H), 1.54 (s, 3H), 1.30 (m,17H), 1.14 (m, 1H), 0.90 (t, J=8.0 Hz, 3H). MS (EI⁺): m/z (%): 431 (M⁺,100), 164 (77), 57 (20). HRMS: m/z [M⁺] calcd. for C₂₆H₄₁NO₄: 431.3036,found: 431.3030.

Example 5:(+)-2,5,7,8-tetramethyl-2-[(E)-5-nitrohex-4-en-1-yl]chroman-6-ol Step 1.Preparation of tert-butyl2-(4-hydroxybut-1-enyl)-2,5,7,8-tetramethylchroman-6-yl carbonate

A suspension of the phosphonium salt (1 mmol) in dry THF (10 mL) at roomtemperature under argon was treated dropwise with a THF solution ofLiHMDS (0.9 M in THF, 2.5 mmol) via a syringe. The red ylide was stirredfor 1 h under argon, and then a solution of6-((tert-butoxycarbonyl)oxy)-2,5,7,8-tetramethylchroman-2-carbaldehyde(1 mmol) in THF was added dropwise. The color changed from red to paleyellow. The resulting suspension was stirred for an additional 3 h untilaldehyde could not be detected by TLC. The reaction was quenched withsaturated NH₄Cl (25 mL) and water (25 mL) and then extracted with ethylacetate. After solvent removal, trituration with cold hexane removedtriphenylphosphine oxide. Concentration of the hexane solution andpurification by column chromatography on silica gel rendered the desiredproduct.

Step 2. Preparation of tert-butyl2-(4-hydroxybutyl)-2,5,7,8-tetramethylchroman-6-yl carbonate

To a solution of tert-butyl2-(4-hydroxybut-1-enyl)-2,5,7,8-tetramethylchroman-6-yl carbonate (1mmol) in ethyl acetate (20 mL) was added 140 mg of 10% Pd/C, and thereaction mixture was attached to a hydrogen balloon for 18 h. Filteringand evaporation afforded desired compound. The product was directly usedfor next step without any purification.

Step 3. Preparation of tert-butyl2-(4-oxobutyl)-2,5,7,8-tetramethylchroman-6-yl carbonate

To a solution of tert-butyl2-(4-hydroxybutyl)-2,5,7,8-tetramethylchroman-6-yl carbonate (1.5 mmol)and TEMPO (0.32 mmol) in acetone, (diacetoxyiodo)benzene (2.0 mmol) wasadded. After 20 h of stirring at room temperature the reaction mixturewas washed with water and extracted with diethyl ether. The organiclayers were dried with Na₂SO₄, filtered and the solvent was evaporatedunder reduced pressure. The residue was loaded onto a silica gen flashcolumn and eluted with hexane: ethyl acetate to afford the desireproduct.

Step 4. Preparation of tert-butyl 2-(5-nitrohex-4-en-1-yl)2,5,7,8-tetramethyl-chroman-6-yl carbonate

Aldehyde tert-butyl 2-(4-oxobutyl)-2,5,7,8-tetramethylchroman-6-ylcarbonate (1 mmol) was added in a mixture of nitroethane (3 mL) andequivalent amount of CH₃COONH₄. The mixture was stirred at 100° C. for 2h. The solvent was then evaporated and water and diethyl ether wereadded. The organic layer was washed with H2O, HCl 1N, and saturatedaqueous NaCl, dried, and the solvent was evaporated. The crude residuewas purified by column chromatography affording the desired nitrovinylcompound.

Step 5. Preparation of(+)-2,5,7,8-tetramethyl-2-[(E)-5-nitrohex-4-en-1-yl]chroman-6-ol

To a solution of tert-butyl 2-(5-nitrohex-4-en-1-yl)2,5,7,8-tetramethyl-chroman-6-yl carbonate (1 mmol) in DCM, TFA (22mmol) was added and the reaction was stirred for 2 h at roomtemperature. Then, the reaction mixture was washed with NaHCO₃ saturatedsolution and brine. The organic layers were dried with Na₂SO₄, filteredand solvent evaporated under reduced pressure. The residue was loadedonto a silica gel flash column and eluted with hexane: ethyl acetate toafford final product.

Biologic Activity

The following methods described are used in order to demonstratebiological activity and therapeutic use, and should not to be construedin any way as limiting the scope of the invention.

In Vitro Activity

As shown in FIG. 1A, 130 μM of2,5,7,8-tetramethyl-2-[(E)-2-nitrovinyl]chroman-6-ol (NAT×0) wasincubated with 1 mM of β-mercaptoethanol (Sigma) in 100 mM pH7 phosphatebuffer. UV-visible spectra was acquired by a Varian Cary 50 Bio. Scanswere taken every min up to 15 min.

The reaction between NAT×0 and β-mercaptoethanol (BME) showed decreasein the absorbance at the maximums at 285 nm and showed increase at the260 nm wavelength as shown in FIG. 1B. The increase at 260 nmdemonstrates adduct formation between NAT×0 and BME, and the decrease ofthe maximums at 285 nm exhibits NAT×0 consumption.

In FIG. 2, it is shown that the reaction between NAT×0 and BME wasdetermined to be a second order rate constant. Stopped-flow kineticmeasurements were performed using a Rx 2000 stopped flow analyzer(Applied Photophysics). Mixutres of 150 μL NAT×0 (25 μM) and solutionsof BME at 0.54 mM, 1.09 mM, 1.64 mM, 2.18 mM, and 2.73 mMconcentrations.

The reaction was monitored by following the absorbance at 260 nm andplots were fitted to a simple exponential decay function using Originlabsoftware (version 8.0. The observed pseudo first order constant at eachconcentration of BME was extracted from the equation and plotted againstthe concentration of BME. The second rate constant of the reaction isderived from the slope of the curve and was 23.45 M⁻¹s⁻¹. Allexperiments were carried out at 25° C. by triplicate.

In FIG. 3, 130 μM NAT×0 was incubated with 2 mM Glutathione (Sigma) in100 mM pH 7 phosphate buffer. UV-visible spectra was acquired by aVarian Cary 50 Bio. Scans were taken every min up to 15 min. Thereaction between NAT×0 and β-mercaptoethanol (BME) showed decrease inthe absorbance at the maximums at 285 nm and showed increase at the 260nm wavelength. The increase at 260 nm demonstrates adduct formationbetween NAT×0 and BME, and the decrease of the maximums at 285 nmexhibits NAT×0 consumption.

The reaction between NAT×0 and glutathione (GSH) showed decrease in theabsorbance at the maximums at 285 nm and showed increase at the 260 nmwavelength. The increase at 260 nm demonstrates adduct formation betweenNAT×0 and BME, and the decrease of the maximums at 285 nm exhibits NAT×0consumption. The results shown in FIG. 2 further demonstrates thatcompounds within the scope of the present invention form adducts withproteins that modulate cell signaling cascades through Michael additionbetween the electrophilic P3-carbon of the nitroalkene moiety and thenucleophilic thiol contain residues.

FIG. 4 illustrates a second order rate constant of the reaction betweenNAT×0 and GSH. Stopped-flow kinetic measurements were performed using aRx 2000 stopped flow analyzer (Applied Photophysics). Mixutres of 150 LNAT×0 (25 μM) and solutions of BME at 0.54 mM, 1.09 mM, 1.64 mM, 2.18mM, and 2.73 mM concentrations.

The reaction was monitored by following the absorbance at 260 nm andplots were fitted to a simple exponential decay function using Originlabsoftware (version 8.0. The observed pseudo first order constant at eachconcentration of BME was extracted from the equation and plotted againstthe concentration of BME. The second rate constant of the reaction isderived from the slope of the curve and was 23.45 M⁻¹s⁻¹. Allexperiments were carried out at 25° C. by triplicate.

As shown in FIG. 5, Western Blot analysis was performed to investigateHO-1 and GCLM protein expression after exposure to the NATx compoundsincluding NAT×0 and2,5,7,8-tetramethyl-2-[(E)-2-nitropent-1-enyl]chroman-6-ol (NAT×5). Raw264.7 cells, a murine macrophage cell line catalog no. TIB-71TM (ATCC,Manassas, Va.), were treated with NAT×0 or NAT×5 (5 μM) for 18 hours.Cells were lysed, and total protein concentration was measured withPierce BCA assay (Thermo Fisher Scientific, Rockford, Ill.). Forelectrophoresis, 30 μg of protein was used in each line. The proteinswere electrophoresed on a Tris/glycine SDS-polyacrylamide gradient gel(10-15%) and transferred to nitrocellulose membrane. The primaryantibodies used for detection was rabbit polyclonal anti-HO-1 oranti-GCLM (Abcam, Cambridge, Mass.). Blots were visualized usinghorseradish peroxidase-conjugated secondary antibodies and ECL Plusdetection system (GE Healthcare, Little Chalfont, UK). Blots weredetected with a scanner. Protein expression was quantified withImageQuant TL7.0 software (GE Healthcare, Little Chalfont, UK). Theresults shown demonstrate that Both NATx compounds induced theexpression of HO-1 and GCLM, under the control of the Nrf2/Keap1 system.

FIGS. 6A and 6B illustrate the effect of NAT×0 on cell viability andNLRP3 inflammasome activation. THP-1 cells were differentiated intomacrophages (PMA 200 nM, 48 hours). As shown in FIG. 6A, the cells werethen stimulated with LPS (first signal; 250 ng/mL, 3 hours).Subsequently, as shown in FIG. 6B, the cells were stimulated with ATP(second signal; 5 mM, 45 minutes). The cells were treated with NAT×0 at0.5 μM, 1.0 μM, 2.5 μM, 5.0 μM, 10 μM, and 20 μM concentrations togetherwith the first signal or the second signal. Cell viability was measuredby MTT assay. Supernatant was stored.

In FIGS. 7A and 7B, supernatant stored from the previously describedexperiment were measured for IL-1β by ELISA.

FIGS. 6 and 7 demonstrate that NAT×0 does not induce an increase in cellmortality induced by the activation of the cells by LPS or ATP, nor didit protect the cells. On the other hand, NAT×0 inhibited inflammasomeactivation in dose dependent manner when applied together with thesecond signal. At the first signal, we only observed a full inhibitionof the inflammasome at 20 μM.

FIG. 8 NAT×0 cell cytotoxicity was evaluated in RAW 264.7 cells at 1, 5,10, 50 and 100 M in DMSO. Cells were treated for 24 h with NAT×0 andthen MTT assay was performed. The absorbance at 570 nm was measured foreach condition by triplicate. The % cell ability was calculated usingcontrol group (DMSO, without treatment). The half maximal inhibitoryconcentration (IC₅₀) was calculated after % cell viability was plottedagainst the concentration of NAT×0 and fitted to an exponential functionusing OriginLab software (version 8.0). The IC₅₀ for NAT×0 in RAW 264.7cells was calculated to be 24 μM.

FIG. 9 illustrates control of the hydrophilicity of embodiments oftrolox derivatives described herein. Reverse phase chromatography wasperformed on a C30 column at 1.5 ml/min. The solvents used were A: H₂Oand methanol (MeOH). The gradient used was 75% MeOH from 0 to 3 minutesand 100% MeOH from 3 to 10 minutes. Compounds were detected at 266 nmwith a 10 nmol injection volume.

FIG. 10 presents the incubation of NAT×0 incubated in PEG 300 to PEG 400at 37° C. for two weeks. At each time point, an aliquot was extractedwith methanol and analyzed by reverse phase chromatography as before.After two weeks in 37° C. in PEG, 50% of the initial concentration ofNAT×0 was recovered.

Nuclear factor kappa B (NF-κB) represents a family of pro-inflammatorytranscription factors, present in all eukaryotic cells, which regulateinducible expression of wide ranging genes involved in immune responsesand cell-cycle regulation. Activation of NF-κB is accompanied by nucleartranslocation of NF-κB. Accordingly, FIG. 11 illustrates the lack ofnuclear translocation of NF-κB in the presence of nitroalkene troloxderivatives to further demonstrate anti-inflammatory effects.Specifically, FIG. 11 illustrates immunofluorescence and epifluorescencemicroscopy analysis showing the effect of NAT×0 on LPS-induced NF-κB/p65subcellular localization in THP-1 macrophages. Cells treated with NAT×0(10 uM, 2 hs before) and then activated with LPS (1 ug/mL) show nochange from the negative control (Ctrl−) cells which were not treatedwith LPS. However, the cells that were not treated with NAT×0 andactivated with LPS showed nuclear translocation of NF-κB p65 dimerstagged with Alexa 488 antibodies.

In Vivo Activity

In vivo testing was carried out in C57BL/6 mice. The mice were injectedintraperitoneally (“i.p.”) with 20 mg/kg NAT×0 or a control (DMSO) 1hour before i.p. injection of 10 mg/kg LPS Escherichia coli 055:B5(Sigma-Aldrich). After 2 hours the mice were killed, and serum levels ofIL-1β were measured by ELISA to determine inflammatory response. FIG. 12illustrates that the inflammatory response did not increase in miceinjected with NAT×0, whereas the mice injected with the control showeddramatic increases indicating NAT×0 is a potent anti-inflammatory agent.

Non-Patent Citations

-   1. Kansanen, E., Jyrkkanen, H. K., Volger, O. L., Leinonen, H.,    Kivela, A. M., Hakkinen, S. K., Woodcock, S. R., Schopfer, F. J.,    Horrevoets, A. J., Yla-Herttuala, S., Freeman, B. A., and    Levonen, A. L. (2009) Nrf2-dependent and -independent responses to    nitro-fatty acids in human endothelial cells: identification of heat    shock response as the major pathway activated by nitro-oleic acid, J    Biol Chem 284, 33233-33241.-   2. Batthyany C, Schopfer F J, Baker P R, Duran R, Baker L M, Huang    Y, Cervenansky C, Branchaud B P, Freeman B A (2006) Reversible    post-translational modification of proteins by nitrated fatty acids    in vivo. J Biol Chem 281: 20450-20463.-   3. Motohashi, H., and Yamamoto, M. (2004) Nrf2-Keap1 defines a    physiologically important stress response mechanism, Trends Mol Med    10, 549-557.-   4. Khoo, N. K., and Freeman, B. A. (2010) Electrophilic nitro-fatty    acids: anti-inflammatory mediators in the vascular compartment,    Current opinion in pharmacology 10, 179-184.-   5. Holtzclaw, W. D., Dinkova-Kostova, A. T., and Talalay, P. (2004)    Protection against electrophile and oxidative stress by induction of    phase 2 genes: the quest for the elusive sensor that responds to    inducers, Adv Enzyme Regul 44, 335-367.-   6. Levonen, A. L., Inkala, M., Heikura, T., Jauhiainen, S.,    Jyrkkanen, H. K., Kansanen, E., Maatta, K., Romppanen, E., Turunen,    P., Rutanen, J., and Yla-Herttuala, S. (2007) Nrf2 gene transfer    induces antioxidant enzymes and suppresses smooth muscle cell growth    in vitro and reduces oxidative stress in rabbit aorta in vivo,    Arterioscler Thromb Vasc Biol 27, 741-747.-   7. Talalay, P., Dinkova-Kostova, A. T., and Holtzclaw, W. D. (2003)    Importance of phase 2 gene regulation in protection against    electrophile and reactive oxygen toxicity and carcinogenesis, Adv    Enzyme Regul 43, 121-134.-   8. Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D.,    Kang, M. I., Kobayashi, A., Yamamoto, M., Kensler, T. W., and    Talalay, P. (2004) Protection against electrophile and oxidant    stress by induction of the phase 2 response: fate of cysteines of    the Keap1 sensor modified by inducers, Proc Natl Acad Sci USA 101,    2040-2045.-   9. Kansanen, E., Bonacci, G., Schopfer, F. J., Kuosmanen, S. M.,    Tong, K. I., Leinonen, H., Woodcock, S. R., Yamamoto, M., Carlberg,    C., Yla-Herttuala, S., Freeman, B. A., and Levonen, A. L. (2011)    Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine    151-independent mechanism, J Biol Chem 286, 14019-14027.-   10. Abraham, N. G., and Kappas, A. (2005) Heme oxygenase and the    cardiovascular-renal system, Free radical biology & medicine 39,    1-25.-   11. Baker, P. R., Schopfer, F. J., O'Donnell, V. B., and    Freeman, B. A. (2009) Convergence of nitric oxide and lipid    signaling: anti-inflammatory nitro-fatty acids, Free radical biology    & medicine 46, 989-1003.-   12. Cock T A, Houten S M, Auwerx J (2004) Peroxisome    proliferator-activated receptor-gamma: too much of a good thing    causes harm. EMBO Rep 5: 142-147.-   13. Baker P R, Schopfer F J, O'Donnell V B, Freeman B A (2009)    Convergence of nitric oxide and lipid signaling: anti-inflammatory    nitro-fatty acids. Free Radic Biol Med 46: 989-1003.-   14. Yu K, Bayona W, Kallen C B, Harding H P, Ravera C P, McMahon G,    Brown M, Lazar M A (1995) Differential activation of peroxisome    proliferator-activated receptors by eicosanoids. J Biol Chem 270:    23975-23983.-   15. Shiraki T, Kamiya N, Shiki S, Kodama T S, Kakizuka A, Jingami    H (2005) Alpha,beta-unsaturated ketone is a core moiety of natural    ligands for covalent binding to peroxisome proliferator-activated    receptor gamma. J Biol Chem 280: 14145-14153.-   16. Elbrecht A, Chen Y, Adams A, Berger J, Griffin P, Klatt T, Zhang    B, Menke J, Zhou G, Smith R G, Moller D E (1999) L-764406 is a    partial agonist of human peroxisome proliferator-activated receptor    gamma. The role of Cys313 in ligand binding. J Biol Chem 274:    7913-7922.-   17. Khoo N K, Freeman B A (2010) Electrophilic nitro-fatty acids:    anti-inflammatory mediators in the vascular compartment. Curr Opin    Pharmacol 10: 179-184.-   18. Li Y, Zhang J, Schopfer F J, Martynowski D, Garcia-Barrio M T,    Kovach A, Suino-Powell K, Baker P R, Freeman B A, Chen Y E, Xu H    E (2008) Molecular recognition of nitrated fatty acids by PPAR    gamma. Nat Struct Mol Biol 15: 865-867.-   19. Schopfer F J, Cole M P, Groeger A L, Chen C S, Khoo N K,    Woodcock S R, Golin-Bisello F, Motanya U N, Li Y, Zhang J,    Garcia-Barrio M T, Rudolph T K, Rudolph V, Bonacci G, Baker P R, Xu    H E, Batthyany C I, Chen Y E, Hallis T M, Freeman B A (2010)    Covalent peroxisome proliferator-activated receptor gamma adduction    by nitro-fatty acids: selective ligand activity and anti-diabetic    signaling actions. J Biol Chem 285: 12321-12333.-   20. Bouhlel M A, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon    S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B,    Chinetti-Gbaguidi G (2007) PPARgamma activation primes human    monocytes into alternative M2 macrophages with anti-inflammatory    properties. Cell Metab 6: 137-143.-   21. Rudolph V, Schopfer F J, Khoo N K, Rudolph T K, Cole M P,    Woodcock S R, Bonacci G, Groeger A L, Golin-Bisello F, Chen C S,    Baker P R, Freeman B A (2009) Nitro-fatty acid metabolome:    saturation, desaturation, beta-oxidation, and protein adduction. J    Biol Chem 284: 1461-1473.-   22. Rudolph, V., Schopfer, F. J., Khoo, N. K., Rudolph, T. K.,    Cole, M. P., Woodcock, S. R., Bonacci, G., Groeger, A. L.,    Golin-Bisello, F., Chen, C. S., Baker, P. R., and    Freeman, B. A. (2009) Nitro-fatty acid metabolome: saturation,    desaturation, beta-oxidation, and protein adduction. J Biol Chem    284, 1461-73.

What is claimed is:
 1. A method of treating an inflammation relateddisorder comprising the steps of administering to a subject in needthereof a therapeutically effective amount of a compound of Formula I:

or a pharmaceutically-acceptable salt thereof, wherein R is a C₁-C₁₅nitroalkenyl; R¹, R², R⁴, and R⁵ are independently a —H or —CH₃; and R³is selected from the group consisting of —H, —OH, —OBOC, —OCH₃, —OBn,—SH, —NO₂, —NH₂, —CN, a carbonyl, a sulfonate, an amidino.
 2. The methodof treating an inflammation related disorder of claim 1, wherein theinflammation related disorder is selected from the group consisting ofatherosclerosis, obesity, metabolic syndrome, arterial hypertension(HTA), acne vulgaris, asthma, autoimmune diseases, autoinflammatorydiseases, celiac disease, chronic prostatitis, glomerulonephritis,inflammatory bowel diseases, pelvic inflammatory disease, reperfusioninjury, rheumatoid arthritis, sacroidosis, transplant rejection,vasculitis, and interstitial cystitis.
 3. The method of treating aninflammation related disorder of claim 1 comprising the steps ofadministering to a subject in need thereof a therapeutically effectiveamount of the compound of Formula I:

wherein R³ is selected from the group consisting of —H, a —OH, —OBOC,—OCH₃, and —OBn.
 4. The method of treating an inflammation relateddisorder of claim 1, wherein R¹, R², R⁴, and R⁵ are each —CH₃.
 5. Themethod of treating an inflammation related disorder of claim 1, whereinR is a nitrovinyl.
 6. The method of treating an inflammation relateddisorder of claim 1, wherein R³ is —OH.
 7. The method of treating aninflammation related disorder of claim 1, wherein the compound ofFormula I is selected from the group consisting of:2,5,7,8-tetramethyl-2-(2-nitrovinyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitropentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitro-2-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-2-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-3-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-3-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-4-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-4-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitrooctenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitro-2-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-2-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-3-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-3-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-4-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-4-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-5-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(6-nitro-5-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(6-nitro-6-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(7-nitro-6-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(7-nitro-7-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(8-nitro-7-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitrotridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitro-2-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-2-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-3-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-3-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-4-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-4-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-5-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(6-nitro-5-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(6-nitro-6-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(7-nitro-6-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(7-nitro-7-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(8-nitro-7-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(8-nitro-8-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(9-nitro-8-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(9-nitro-9-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(10-nitro-9-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(10-nitro-10-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(11-nitro-10-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(11-nitro-11-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(12-nitro-11-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(12-nitro-12-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(13-nitro-12-tridecenyl)chroman-6-ol, or aphysiologically acceptable salt thereof.
 8. The method of treating aninflammation related disorder of claim 1, wherein the compound ofFormula I is 2,5,7,8-tetramethyl-2-(2-nitrovinyl)chroman-6-ol or aphysiologically acceptable salt thereof.
 9. The method of treating aninflammation related disorder of claim 1, wherein the compound ofFormula I is (2S)-2,5,7,8-tetramethyl-2-[(E)-2-nitrovinyl]chroman-6-olor a physiologically acceptable salt thereof.
 10. The method of treatingan inflammation related disorder of claim 1, wherein R is a 2-nitrovinyland the absolute configuration of the chiral carbon adjacent the oxygenatom on the chromanol ring structure is (S).
 11. The method of treatingan inflammation related disorder of claim 1, wherein R is a2-nitroalkenyl and the absolute configuration of the chiral carbonadjacent the oxygen atom on the chromanol ring structure is (S).
 12. Themethod of treating an inflammation related disorder of claim 1, whereinR is a 3-nitroallyl and the absolute configuration of the chiral carbonadjacent the oxygen atom on the chromanol ring structure is (S).
 13. Themethod of treating an inflammation related disorder of claim 1, whereinR is a 3-nitroalkenyl and the absolute configuration of the chiralcarbon adjacent the oxygen atom on the chromanol ring structure is (S).14. The method of treating an inflammation related disorder of claim 1,wherein R has a nitroalkenyl disposed at fourth to fifteenth carbon onthe C₄-C₁₅ hydrocarbon tail and the absolute configuration of the chiralcarbon adjacent the oxygen atom on the chromanol ring structure is (R).15. A method of treating an inflammation related disorder comprising thesteps of administering to a subject in need thereof a pharmaceuticalcomposition comprising a carrier and a therapeutically effective amountof a compound of Formula I:

or a pharmaceutically-acceptable salt thereof, wherein R is a C₁-C₁₅nitroalkenyl; R¹, R², R⁴, and R⁵ are independently a —H or —CH₃; and R³is selected from the group consisting of —H, —OH, —OBOC, —OCH₃, —OBn,—SH, —NO₂, —NH₂, —CN, a carbonyl, a sulfonate, an amidino.
 16. Themethod of treating an inflammation related disorder of claim 15, whereinR is a nitrovinyl.
 17. The method of treating an inflammation relateddisorder of claim 15, wherein R³ is —OH.
 18. The method of treating aninflammation related disorder of claim 15, wherein the compound ofFormula I is selected from the group consisting of:2,5,7,8-tetramethyl-2-(2-nitrovinyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitropentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitro-2-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-2-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-3-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-3-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-4-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-4-pentenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitrooctenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitro-2-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-2-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-3-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-3-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-4-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-4-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-5-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(6-nitro-5-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(6-nitro-6-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(7-nitro-6-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(7-nitro-7-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(8-nitro-7-octenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitrotridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(2-nitro-2-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-2-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(3-nitro-3-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-3-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(4-nitro-4-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-4-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(5-nitro-5-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(6-nitro-5-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(6-nitro-6-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(7-nitro-6-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(7-nitro-7-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(8-nitro-7-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(8-nitro-8-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(9-nitro-8-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(9-nitro-9-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(10-nitro-9-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(10-nitro-10-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(11-nitro-10-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(11-nitro-11-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(12-nitro-11-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(12-nitro-12-tridecenyl)chroman-6-ol,2,5,7,8-tetramethyl-2-(13-nitro-12-tridecenyl)chroman-6-ol, or aphysiologically acceptable salt thereof.
 19. The method of treating aninflammation related disorder of claim 15, wherein the compound ofFormula I is 2,5,7,8-tetramethyl-2-(2-nitrovinyl)chroman-6-ol or aphysiologically acceptable salt thereof.
 20. The method of treating aninflammation related disorder of claim 19, wherein the compound ofFormula I is (2S)-2,5,7,8-tetramethyl-2-[(E)-2-nitrovinyl]chroman-6-olor a physiologically acceptable salt thereof.